GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Modalis Therapeutics Corp (TSE:4883) » Definitions » Net Interest Income (for Banks)

Modalis Therapeutics (TSE:4883) Net Interest Income (for Banks)


View and export this data going back to 2020. Start your Free Trial

What is Modalis Therapeutics Net Interest Income (for Banks)?

Net Interest Income only applies to banks.


Modalis Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
16-5 Nihombashi-Kabuto-cho, Chuo-ku, Tokyo, JPN, 103-0026
Modalis Therapeutics Corp is a drug development company. It is engaged in research and development of Gene Therapy using core platform technology, non-editing CRISPR technology (CRISPR-GNDM). The company's products in pipeline are MDL-201, MDL-202, MDL-204, MDL-205, MDL-206, MDL-101, and MDL-102.